PubMed Health⌕ Search

Biomedical subjects

P S Staats

Publications and source records attributed to P S Staats.

At least 19 recordsLinked to original sources
PubMed2005

An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM).

BACKGROUND: The randomized clinical trial of implantable drug delivery systems (IDDS) plus comprehensive medical management (CMM) versus CMM alone showed better clinical success at 4 weeks for IDDS patients. This 'as treated' analysis assessed if improvements in pain control, drug toxicity and survival were maintained over time. PATIENTS AND METHODS: We compared those who received IDDS with those who did not receive IDDS (non-IDDS). All patients had Visual Analogue Scores (VAS) for pain > or =5/10 on at least 200 mg morphine or equivalent daily. RESULTS: At 4 weeks, 46 of 52 (88.5%) IDDS patients achieved clinical success compared with 65 of 91 (71.4%; P=0.02) non-IDDS patients, and more often achieved > or =20% reduction in both pain VAS and toxicity [35 of 52 (67.3%) versus 33 of 91 patients (36.3%); P=0.0003]. By 12 weeks, 47 of 57 (82.5%) IDDS patients had clinical success compared with 35 of 45 (77.8%; P=0.55) non-IDDS patients, and more often had a > or =20% reduction in both pain VAS and toxicity [33 of 57 (57.9%) versus 15 of 45 patients (33.3%); P=0.01]. At 12 weeks the IDDS VAS pain scores decreased from 7.81 to 3.89 (47% reduction) compared with 7.21 to 4.53 for non-IDDS patients (42% reduction; P=0.23). The 12 week drug toxicity scores for IDDS patients decreased from 6.68 to 2.30 (66% reduction), and for non-IDDS patients from 6.73 to 4.13 (37% reduction; P=0.01). All individual drug toxicities improved with IDDS at both 4 and 12 weeks. At 6 months, only 32% of the group randomized to CMM and who did not cross over to IDDS were alive, compared with 52%-59% for patients in those groups who received IDDS. CONCLUSIONS: IDDS improved clinical success, reduced pain scores, relieved most toxicity of pain control drugs, and was associated with increased survival for the duration of this 6 month trial.

Adult↗
PubMed2001

Spinal drug delivery.

Clinicians currently base decisions regarding the use of intrathecal drug therapy for chronic pain on reports from uncontrolled and retrospective studies that fail to rely on standardized outcome measures. In this article, we summarize what is known about currently administered intrathecal therapies, including opioids, gamma-aminobutyric acid agonists, alpha-2 adrenoreceptor agonists, local anesthetics (sodium channel antagonists), calcium channel antagonists, miscellaneous agents, and drug combination therapy. In addition, we offer a brief look at novel approaches that may revolutionize intrathecal drug delivery.

Analgesics↗
PubMed2001

The effects of alcohol celiac plexus block, pain, and mood on longevity in patients with unresectable pancreatic cancer: a double-blind, randomized, placebo-controlled study.

OBJECTIVE: This additional analysis of data from a previously reported prospective trial comparing the effect of intraoperative alcohol or saline placebo neurolytic block in patients with pancreatic cancer was conducted in response to the development of a new theory, which explores the relationship of negative mood states to pain, pain-related behavior, and ultimately, longevity. METHODS: The original study used a double-blind procedure to randomly assign 139 patients with histologically proven, unresectable pancreatic cancer to receive either an alcohol or a saline block. Data on visual analog pain, mood, and interference with activity were collected preoperatively and every 2 months postoperatively until death. The current analysis was conducted on the complete data sets received from 130 patients. Demographic data were submitted to chi-square analysis and to univariate and multivariate analysis of variance. Univariate and multivariate analyses of variance also compared 1) the effect of alcohol versus saline on pain, mood, interference of pain with activities, and longevity and 2) the impact of mood on pain with longevity as the dependent variable. Correlation and regression analyses examined the impact of mood on life expectancy. RESULTS: The alcohol intervention had a significant positive effect on life duration and mood scores. High negative mood states correlated significantly with an increase in visual analog pain, the rating of pain intensity at its worse, and pain interference with patients' activities. CONCLUSION: In these subjects, the neurolytic block, as compared with medical management alone, improved pain, elevated mood, reduced pain interference with activity, and was associated with an increase in life expectancy.

Clinical Trial↗
PubMed2001

The additive impact of anxiety and a placebo on pain.

OBJECTIVE: We investigated the effects of pain anxiety and a placebo/nocebo/neutral intervention on ice water-induced pain. DESIGN: We divided 72 volunteers into high- and low-anxiety groups before randomly assigning them to experimental and control subgroups. METHOD: Participants completed preimmersion tests of pain anxiety, pain worry, and mood. We scored first immersion pain behavior, experience, and intensity. Each subgroup then received an instruction designed to elicit a positive (placebo), negative (nocebo), or neutral response. After repeating the pain worry test, we gathered second immersion pain scores, and participants repeated the mood test, completed the treatment credibility measure, and were debriefed. OUTCOME MEASURES: We used the Pain Anxiety Symptom Scale; self-rating Likert-type scales for pain worry, pain intensity, and pain-coping; the Multiple Affect Adjective Checklist (mood); timed measurements for pain threshold and pain tolerance; and a treatment credibility scale. RESULTS: Pain anxiety and the placebo interventions significantly altered participants' pain scores, with best-to-worse scores reported by the low pain-anxiety/placebo, high anxiety/placebo, low anxiety/neutral, low anxiety/nocebo, high anxiety neutral, and high anxiety/nocebo groups. The high pain-anxiety group demonstrated the greatest response to the placebo/nocebo intervention in the expected directions in pain, worry, and anxious mood scores and in decreased self-confidence in managing pain (this was also negatively affected by the nocebo in each pain-anxiety group). CONCLUSION: This study demonstrates that the interaction of the personality variable of pain anxiety with the placebo/nocebo response has an impact on pain, worry, and mood.

Clinical Trial↗
PubMed1999

Management of chronic pain.

Chronic pain is a common condition for which patients seek care from various health-care providers. This type of pain causes much suffering and disability and is frequently mistreated or undertreated. Patients who present for evaluation for chronic pain should undergo a careful assessment before therapy. Patients with chronic pain commonly experience depression, sleep disturbance, fatigue, and decreased overall physical and mental functioning. They frequently require an interdisciplinary model of care to allow care givers to address the multiple components of the patient's pain experience. After a careful evaluation, therapy may include medication, nerve blocks, active physical therapy, behavioural interventions, and assistance with vocational evaluation and training. Less frequently therapy may include placement of implantable devices to alter the pain experience. These patients suffer from a chronic condition and often require long-term care, with frequent reassessment and adjustment of therapy. Although cure is possible, it is also infrequent. Therefore, therapy is provided with the aim of decreasing pain and suffering while improving physical and mental functioning.

Chronic Disease↗
PubMed1999

Neuraxial infusion for pain control: when, why, and what to do after the implant.

Neuraxial infusion therapy is an excellent option for selected patients with severe pain. Both epidural and intrathecal systems can be effective for multiple pains and are titratable, nondestructive, and very safe. Intraspinal therapy requires low opioid doses, has no motor, sensory, or sympathetic effects, and may have a lower side-effect liability than systemic therapy. Although most oncologists do not refer patients for intrathecal therapy, a recent study indicated that more oncologists would if they knew more about the therapy and if patients requested it. When permanent systems are used, close follow-up is essential. To obtain the maximum benefit from intraspinal therapy, pain management physicians and oncologists must communicate with each other and work together as partners.

Analgesics, Opioid↗
PubMed1998

Treatment of intractable pain with topical large-dose capsaicin: preliminary report.

UNLABELLED: Complex regional pain syndromes (CRPS) and neuropathic pain are often poorly controlled by conventional pharmacologic interventions. We administered 8-methyl-N-vanillyl-noneamide (capsaicin) at doses of 5%-10% to individuals with such disorders in this trial. Previous limitations to trials with larger-dose, topical concentrations of capsaicin included intense burning sensations experienced after application. To enable patients to tolerate the high concentrations, we first performed regional anesthesia. All patients reported at least some relief. Of 10 patients, 9 obtained substantial analgesia that lasted 1-18 wk. At Week 1 after therapy, the mean verbal analog scale (VAS) scores decreased from 8.0 to 3.0. At Week 4 after therapy, mean VAS score was 4.5. Analgesia lasted from < 1 wk (1 patient) to more than 50 wk (1 patient). Patients received one to eight treatments. With one exception, patients receiving more than one treatment obtained additional relief with subsequent treatment. Pain responsive to opioids was the only side effect of treatment. Large-dose capsaicin administered with regional anesthesia may effectively minimize refractory CRPS and neuropathic pain. A double-blind, placebo-controlled study in patients with bilateral peripheral neuropathy using epidural anesthesia with and without large-dose topical capsaicin is in progress. IMPLICATIONS: Sensory neuropathies are associated with many diseases. Pain from these disorders can produce greater disability than the primary disease processes themselves. Currently available therapies are limited. However, the intermittent application of large-dose topical capsaicin may provide significant pain relief, decrease chronic analgesic dependence, and decrease aggregate health care expenditures.

Administration, Topical↗
PubMed1995

Celiac plexus blockade in a 7-year-old child with neuroblastoma.

Celiac plexus blockade with ethanol is a widely accepted modality of pain control for adults with cancer pain. The role of interventional strategies in children is less well established. A 7-year-old child with abdominal pain secondary to a Wilms tumor was treated with neurolytic celiac plexus blockade. This resulted in control of abdominal pain for close to three months. This modality is underutilized and should be considered for children with pain due to upper abdominal malignancy.

Adrenal Gland Neoplasms↗